Fletcher Edward J R, Finlay Clare J, Amor Lopez Ana, Crum William R, Vernon Anthony C, Duty Susan
Wolfson Centre for Age Related Diseases, Wolfson Wing, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Front Neurosci. 2020 Sep 15;14:567222. doi: 10.3389/fnins.2020.567222. eCollection 2020.
Dyskinesia associated with chronic levodopa treatment in Parkinson's disease is associated with maladaptive striatal plasticity. The objective of this study was to examine whether macroscale structural changes, as captured by magnetic resonance imaging (MRI) accompany this plasticity and to identify plausible cellular contributors in a rodent model of levodopa-induced dyskinesia. Adult male Sprague-Dawley rats were rendered hemi-parkinsonian by stereotaxic injection of 6-hydroxydopamine into the left medial forebrain bundle prior to chronic treatment with saline (control) or levodopa to induce abnormal involuntary movements (AIMs), reflective of dyskinesia. Perfusion-fixed brains underwent structural MRI before sectioning and staining for cellular markers. Chronic treatment with levodopa induced significant AIMs ( < 0.0001 versus saline). The absolute volume of the ipsilateral, lesioned striatum was increased in levodopa-treated rats resulting in a significant difference in percentage volume change when compared to saline-treated rats ( < 0.01). Moreover, a significant positive correlation was found between this volume change and AIMs scores for individual levodopa-treated rats ( = 0.96; < 0.01). The density of Iba1+ cells was increased within the lesioned versus intact striatum ( < 0.01) with no difference between treatment groups. Conversely, Iba1+ microglia soma size was significantly increased ( < 0.01) in the lesioned striatum of levodopa-treated but not saline-treated rats. Soma size was not, however, significantly correlated with either AIMs or MRI volume change. Although GFAP+ astrocytes were elevated in the lesioned versus intact striatum ( < 0.001), there was no difference between treatment groups. No statistically significant effects of either lesion or treatment on RECA1, a marker for blood vessels, were observed. Collectively, these data suggest chronic levodopa treatment in 6-hydroxydopamine lesioned rats is associated with increased striatal volume that correlates with the development of AIMs. The accompanying increase in number and size of microglia, however, cannot alone explain this volume expansion. Further multi-modal studies are warranted to establish the brain-wide effects of chronic levodopa treatment.
帕金森病中与慢性左旋多巴治疗相关的运动障碍与纹状体适应性不良可塑性有关。本研究的目的是检查磁共振成像(MRI)所捕捉到的宏观结构变化是否伴随这种可塑性,并在左旋多巴诱导的运动障碍的啮齿动物模型中确定可能的细胞因素。成年雄性Sprague-Dawley大鼠在立体定向注射6-羟基多巴胺至左侧内侧前脑束使其半帕金森病化后,分别用生理盐水(对照)或左旋多巴进行慢性治疗以诱导异常不自主运动(AIMs),这反映了运动障碍。灌注固定的大脑在切片和进行细胞标记染色之前先进行结构MRI检查。左旋多巴慢性治疗诱导了显著的AIMs(与生理盐水相比,<0.0001)。左旋多巴治疗的大鼠中,同侧受损纹状体的绝对体积增加,与生理盐水治疗的大鼠相比,体积变化百分比有显著差异(<0.01)。此外,在单个左旋多巴治疗的大鼠中,这种体积变化与AIMs评分之间发现显著正相关(=0.96;<0.01)。与完整纹状体相比,受损纹状体内Iba1+细胞的密度增加(<0.01),治疗组之间无差异。相反,在左旋多巴治疗而非生理盐水治疗的大鼠的受损纹状体中,Iba1+小胶质体细胞体大小显著增加(<0.01)。然而,细胞体大小与AIMs或MRI体积变化均无显著相关性。虽然与完整纹状体相比,受损纹状体内GFAP+星形胶质细胞增多(<0.001),但治疗组之间无差异。未观察到损伤或治疗对血管标记物RECA1有统计学显著影响。总体而言,这些数据表明,在6-羟基多巴胺损伤的大鼠中,慢性左旋多巴治疗与纹状体体积增加有关,且与AIMs的发展相关。然而,伴随的小胶质细胞数量和大小的增加并不能单独解释这种体积扩大。有必要进行进一步的多模式研究以确定慢性左旋多巴治疗对全脑的影响。